Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses

Poecheim, Johanna; Barnier-Quer, Christophe; Collin, Nicolas; Borchard, Gerrit

doi:10.3390/vaccines4030032

Cited by 20 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical studies by different research groups have successfully demonstrated the efficacy of NP based vaccines in the induction of specific immune responses against tuberculosis ( 42 , 179 – 182 ). Feng et al developed a NP-based recombinant DNA vaccine that consists of Esat-6 and fms-like tyrosine kinase 3 ligand enveloped with chitosan NPs ( 42 ).…”

Section: Implications Of the Nanocarriers In The Vaccine Developmentmentioning

confidence: 99%

Nanoparticle Vaccines Against Infectious Diseases

2018

View full text Add to dashboard Cite

Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases.

show abstract

Section: Implications Of the Nanocarriers In The Vaccine Developmentmentioning

confidence: 99%

Nanoparticle Vaccines Against Infectious Diseases

2018

View full text Add to dashboard Cite

show abstract

“…Reorganized Ag85A DNA was demonstrated to trigger strong immune reactions, leading to dramatic upregulation of Th1 cytokines (IFN-γ and IL-2), which are crucial mediators of immunity. In turn, the Th1 cytokines functioned by stimulating cytotoxic cells and eliminating infected cells ( 36 – 38 ). In the current study, it was observed that Ag85A-DCs promoted allogeneic T-cell proliferation and increased IFN-γ production.…”

Section: Discussionmentioning

confidence: 99%

Dendritic cell vaccine with Ag85A enhances anti‑colorectal carcinoma immunity

et al. 2018

View full text Add to dashboard Cite

Dendritic cells (DCs) are able to trigger T-cell activation and thus have been considered important for vaccine production against cancers. Vaccines containing DCs have been reported to be effective for developing immunity against cancer cells. The interactions between DCs and auxiliary agents are critical in the development of second-generation vaccines. In the present study, it was evaluated whether Ag85A-mixed DCs could enhance anti-tumor immunity in laboratory mice with colorectal carcinoma. Functional and phenotypic analyses of the effects of Ag85A-mixed DCs were conducted via flow cytometry and measurement of T-cell proliferation. In addition, interferon (IFN)-γ production was assessed. The therapeutic efficacy of DC vaccination for colorectal carcinoma treatment in mice was investigated. It was identified that Ag85A-mixed DCs exhibited strong upregulation of CD80, CD86 and major histocompatibility complex class II. Cytotoxic T-lymphocytes with CT26-primed Ag85A-DCs were indicated to induce stronger responses against CT26 tumor cells and trigger IFN-γ production. Furthermore, the Ag85A-mixed DC vaccine exerted a considerable inhibitory effect on tumor progression in mice as compared with the control group. Therefore, DCs in combination with the Ag85A gene may reinforce anti-colorectal carcinoma immunity. The current study provides a novel potential strategy for cancer treatment by enhancing immunity via Ag85A-mixed DC vaccination.

show abstract

“…82 Intramuscular immunization with pDNA encoding antigen 85A of M. tuberculosis provoked a significant Th1 response in mice. 83 Many routes have been explored for TMC vaccination. However, there is scope for further intervention into new routes.…”

Section: Route Of Administrationmentioning

confidence: 99%

Novel application of trimethyl chitosan as an adjuvant in vaccine delivery

Malik

Gupta

et al. 2018

IJN

View full text Add to dashboard Cite

The application of natural carbohydrate polysaccharides for antigen delivery and its adjuvanation potential has garnered interest in the scientific community in the recent years. These biomaterials are considered favorable candidates for adjuvant development due to their desirable properties like enormous bioavailability, non-toxicity, biodegradability, stability, affordability, and immunostimulating ability. Chitosan is the one such extensively studied natural polymer which has been appreciated for its excellent applications in pharmaceuticals. Trimethyl chitosan (TMC), a derivative of chitosan, possesses these properties. In addition it has the properties of high aqueous solubility, high charge density, mucoadhesive, permeation enhancing (ability to cross tight junction), and stability over a range of ionic conditions which makes the spectrum of its applicability much broader. It has also been seen to perform analogously to alum, complete Freund’s adjuvant, incomplete Freund’s adjuvant, and cyclic guanosine monophosphate adjuvanation, which justifies its role as a potent adjuvant. Although many review articles detailing the applications of chitosan in vaccine delivery are available, a comprehensive review of the applications of TMC as an adjuvant is not available to date. This article provides a comprehensive overview of structural and chemical properties of TMC which affect its adjuvant characteristics; the efficacy of various delivery routes for TMC antigen combination; and the recent advances in the elucidation of its mechanism of action.

show abstract

Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses

Cited by 20 publications

References 33 publications

Nanoparticle Vaccines Against Infectious Diseases

Nanoparticle Vaccines Against Infectious Diseases

Dendritic cell vaccine with Ag85A enhances anti‑colorectal carcinoma immunity

Novel application of trimethyl chitosan as an adjuvant in vaccine delivery

Contact Info

Product

Resources

About